On April 21, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported its participation in the annual meeting of the German Society for Nuclear Medicine from April 27-30, 2022 (Press release, ITM Isotopen Technologien Munchen, APR 21, 2022, View Source;_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc [SID1234612876]). The conference also represents the 60th anniversary congress of the society and will take place as a hybrid event online and in Leipzig. ITM will host a lunchtime symposium on April 28 on Targeted Radionuclide Therapy – Recent Developments and Radiopharmacy Perspective and will also showcase its precision oncology product portfolio at a booth.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
As part of ITM’s symposium, Prof. Wolfgang Wadsak, Head of Medical Radiochemistry and Biomarker Development in the Clinical Department for Nuclear Medicine at the University Hospital Vienna , will talk about the production of radiopharmaceuticals for direct application in the field of cancer medicine in clinics and as an essential component and innovation driver in nuclear medicine to speak. Neil Quigley, Global Product Manager, ITM , will present the latest developments and potential indications in the field of targeted radionuclide therapy using the alpha emitter Actinium-225. This topic is supplemented by a lecture by Dr. Thomas Gottlieb, Vice President Pharmaceuticals – Commercial Operations, ITM, on development opportunities for the innovative radioisotope actinium-225 and on the worldwide supply security of clinics with the established, high-purity medical radioisotope nca lutetium-177 (no-carrier-added). The symposium is part of the official conference program and will take place on April 28, 2022 from 12:30 pm to 1:30 pm in Hall 2 of the congress building.
"We are pleased to complement the scientific conference program with our symposium. The manufacturing of radiopharmaceuticals in clinics is an essential prerequisite to be able to offer cancer patients targeted radionuclide therapies, while the industry develops ready-to-use radiopharmaceuticals," says Steffen Schuster, CEO of ITM . "With our research and development of precision oncological diagnostics and therapeutics for various cancer indications as well as our current product portfolio of medical radioisotopes and radiolabeling equipment, we want to contribute to giving patients worldwide access to targeted cancer therapies that have the potential to improve treatment outcomes and quality of life."
At booth (#A6) in the conference’s industrial exhibition, ITM will present its proprietary portfolio of high-quality medical radioisotopes, as well as all the equipment needed for manufacturing and quality control of radiopharmaceuticals.
– end –
ITM’s research and development activities in the field of precision oncology
In addition to ITM’s central position in the development, production and distribution of medical radioisotopes and radiolabeling equipment, ITM is developing its own broad pipeline of diagnostic and therapeutic radiopharmaceuticals for various cancer indications. ITM’s lead candidate ITM-11 for the treatment of neuroendocrine tumors of gastroentero-pancreatic origin (GEP-NETs) is currently in two phase III studies, COMPETE and COMPOSE. ITM recently announced the successful completion of patient enrollment for the COMPETE trial evaluating ITM-11 for grade 1 and 2 GEP-NETs . In COMPOSE, ITM-11 will be studied for grade 2 and 3 GEP-NETs in order to evaluate ITM-11 for a broader GEP-NET indication.
Targeted radionuclide therapy
Targeted radionuclide therapy is a new form of cancer therapeutics that aim to irradiate the tumor directly while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are made by combining a therapeutic radioisotope with a targeting molecule (eg, peptide, antibody, small molecule) that can accurately recognize tumor cells and bind to tumor-specific features such as receptors on the surface of the tumor cells. The radioisotope accumulates at the tumor and decays, releasing a small amount of ionizing radiation capable of destroying tumor tissue. The high-precision localization enables targeted treatment with potentially minimal effects on the surrounding healthy tissue.